Ke E Zhang

Author:

Ke Zhang

ISBN #:

7226023601

US Patent:

7265208, Sep 4, 2007

Filed:

May 1, 2001

Appl. No.:

09/847208

Inventors:

Andrew Saxon - Santa Monica CA, US
Ke Zhang - Los Angeles CA, US
Daocheng Zhu - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07K 16/46
C12P 21/08

US Classification:

5303871, 5303873

Abstract:

The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcεRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.

US Patent:

7488804, Feb 10, 2009

Filed:

Feb 2, 2005

Appl. No.:

11/050113

Inventors:

Andrew Saxon - Santa Monica CA, US
Ke Zhang - Los Angeles CA, US
Daocheng Zhu - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12P 21/08

US Classification:

5303873, 4241331, 4241341, 4241441, 4241851, 4241921, 53038822, 530866, 530868

Abstract:

The present invention comprises a fusion molecule comprising a Fcε fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHε2-CHε3-CHε4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgGheavy chain (γhinge-CHγ2-CHγ3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.

US Patent:

7879334, Feb 1, 2011

Filed:

Apr 30, 2007

Appl. No.:

11/799442

Inventors:

Andrew Saxon - Santa Monica CA, US
Ke Zhang - Los Angeles CA, US
Daocheng Zhu - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07K 16/46
A61K 39/00
A61K 39/35
A61K 39/36

US Classification:

4241851, 4241341, 4241921, 4242751, 530350

Abstract:

The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcεRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.

US Patent:

8362322, Jan 29, 2013

Filed:

Oct 26, 2007

Appl. No.:

12/446929

Inventors:

Nestor Apuya - Culver City CA, US
Steven Craig Bobzin - Malibu CA, US
Jack Okamuro - Oak Park CA, US
Ke Zhang - Wilmington DE, US

Assignee:

Ceres, Inc. - Thousand Oaks CA

International Classification:

A01H 5/00
C12N 15/63
C12N 15/82

US Classification:

800284, 800298, 435468, 435419

Abstract:

Materials and methods for modulating (e. g. , increasing or decreasing) lignin content in plants are disclosed. For example, nucleic acids encoding lignin-modulating polypeptides are disclosed as well as methods for using such nucleic acids to generate transgenic plants having a modulated lignin content.

US Patent:

20030059763, Mar 27, 2003

Filed:

Jan 26, 2001

Appl. No.:

09/770169

Inventors:

Andrew Saxon - Santa Monica CA, US
Ke Zhang - Los Angeles CA, US

International Classification:

C12Q001/00

US Classification:

435/004000

Abstract:

This invention concerns class switch recombination (CSR) substrates and assays that permit dissection of the mechanisms involved in CSR and are powerful tools in drug discovery.

US Patent:

20090136493, May 28, 2009

Filed:

Sep 12, 2008

Appl. No.:

12/210120

Inventors:

Andrew Saxon - Santa Monica CA, US
Ke Zhang - Los Angeles CA, US
Daocheng Zhu - Los Angeles CA, US

International Classification:

A61K 39/395
A61K 38/16
A61P 37/08

US Classification:

4241331, 514 12

Abstract:

The present invention comprises a fusion molecule comprising a Fcε fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHε2-CHε3-CHε4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgGheavy chain (γhinge-CHγ2-CH-γ3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.

US Patent:

20110020373, Jan 27, 2011

Filed:

Mar 30, 2007

Appl. No.:

12/294852

Inventors:

Andrew Saxon - Santa Monica CA, US
Ke Zhang - Los Angeles CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 39/395
A61P 31/12
A61P 37/00
A61P 35/04

US Classification:

4241811, 4241781

Abstract:

This invention is directed to a novel approach for focusing and expressing DNA vaccinates in Antigen Presenting Cells (APCs) mediated through targeting IgE receptors (FcεRs) on APC and driving DNA expression through provision of an APC specific regulatory element This vaccine can be used in the prevention or treatment of allergic disease.

US Patent:

55525377, Sep 3, 1996

Filed:

Mar 24, 1993

Appl. No.:

8/037579

Inventors:

Andrew Saxon - Santa Monica CA
Ke Zhang - Los Angeles CA
Edward E. Max - Bethesda MD

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07H 2104
C07H 2102
C12Q 168

US Classification:

536 243

Abstract:

Methods and compositions are provided relating to novel IgE isoforms and their use in immune hypersensitivity diagnosis and treatment. The compositions include transcription and translation products of the immunoglobulin epsilon locus, specific probes for epsilon transcription products, and compounds which specifically bind epitopes of epsilon translation products. Novel products of the epsilon locus include the following transcription products and translation products thereof: CH4-M2", SEQ ID NO:02, residues 1-107 and, (SEQ. ID NO:06, CH4'-CH5-M1'-M2, (see SEQ ID NO:02, residues 1-72,SEQ ID NO:03 and SEQ ID NO:05) CH4'-CH5-M2'(SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:07 and CH4'-CH5-M2" (SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:06). Such epsilon products, specific probes and binding compounds find use in methods and kits for immune hypersensitivity diagnosis and treatment.